Cipla Limited Asset Resilience Ratio
Cipla Limited asset resilience ratio. Cipla Limited (CIPLA) has an Asset Resilience Ratio of 20.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Cipla Limited (CIPLA) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cipla Limited (2004–2025)
Asset resilience ratio of Cipla Limited from 2004 to 2025. This chart shows how Cipla Limited's Asset Resilience Ratio has changed over time. See Cipla Limited free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Cipla Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cipla Limited assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs7.96 Billion | 1.98% |
| Short-term Investments | Rs75.39 Billion | 18.77% |
| Total Liquid Assets | Rs83.35 Billion | 20.75% |
Asset Resilience Insights
- Good Liquidity Position: Cipla Limited maintains a healthy 20.75% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Cipla Limited Industry Peers by Asset Resilience Ratio
Compare Cipla Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
Cipla Limited Asset Resilience Ratio by Year (2004–2025)
Cipla Limited asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for Cipla Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 26.83% | Rs100.32 Billion ≈ $1.08 Billion |
Rs373.87 Billion ≈ $4.04 Billion |
+4.93pp |
| 2024-03-31 | 21.90% | Rs71.65 Billion ≈ $774.91 Million |
Rs327.18 Billion ≈ $3.54 Billion |
+2.49pp |
| 2023-03-31 | 19.41% | Rs57.19 Billion ≈ $618.51 Million |
Rs294.63 Billion ≈ $3.19 Billion |
+4.58pp |
| 2022-03-31 | 14.83% | Rs40.19 Billion ≈ $434.67 Million |
Rs271.01 Billion ≈ $2.93 Billion |
+2.49pp |
| 2021-03-31 | 12.34% | Rs31.03 Billion ≈ $335.55 Million |
Rs251.52 Billion ≈ $2.72 Billion |
+10.48pp |
| 2020-03-31 | 1.86% | Rs4.39 Billion ≈ $47.52 Million |
Rs236.63 Billion ≈ $2.56 Billion |
+1.32pp |
| 2019-03-31 | 0.53% | Rs1.28 Billion ≈ $13.86 Million |
Rs239.63 Billion ≈ $2.59 Billion |
-0.07pp |
| 2018-03-31 | 0.61% | Rs1.39 Billion ≈ $15.05 Million |
Rs228.61 Billion ≈ $2.47 Billion |
+0.55pp |
| 2017-03-31 | 0.06% | Rs118.30 Million ≈ $1.28 Million |
Rs210.37 Billion ≈ $2.28 Billion |
-2.71pp |
| 2016-03-31 | 2.77% | Rs5.85 Billion ≈ $63.26 Million |
Rs211.28 Billion ≈ $2.28 Billion |
+0.29pp |
| 2015-03-31 | 2.48% | Rs3.90 Billion ≈ $42.18 Million |
Rs157.18 Billion ≈ $1.70 Billion |
-0.43pp |
| 2014-03-31 | 2.91% | Rs3.90 Billion ≈ $42.18 Million |
Rs134.03 Billion ≈ $1.45 Billion |
-15.25pp |
| 2013-03-31 | 18.16% | Rs21.17 Billion ≈ $228.92 Million |
Rs116.59 Billion ≈ $1.26 Billion |
+8.10pp |
| 2012-03-31 | 10.06% | Rs9.41 Billion ≈ $101.71 Million |
Rs93.50 Billion ≈ $1.01 Billion |
+7.46pp |
| 2011-03-31 | 2.60% | Rs2.24 Billion ≈ $24.18 Million |
Rs85.97 Billion ≈ $929.70 Million |
+2.59pp |
| 2010-03-31 | 0.01% | Rs5.20 Million ≈ $56.24K |
Rs73.09 Billion ≈ $790.45 Million |
-13.04pp |
| 2009-03-31 | 13.05% | Rs8.95 Billion ≈ $96.78 Million |
Rs68.57 Billion ≈ $741.53 Million |
-6.20pp |
| 2008-03-31 | 19.25% | Rs11.03 Billion ≈ $119.33 Million |
Rs57.33 Billion ≈ $619.96 Million |
+4.05pp |
| 2007-03-31 | 15.20% | Rs6.71 Billion ≈ $72.56 Million |
Rs44.14 Billion ≈ $477.33 Million |
+3.59pp |
| 2006-03-31 | 11.61% | Rs4.01 Billion ≈ $43.42 Million |
Rs34.58 Billion ≈ $374.01 Million |
-3.36pp |
| 2005-03-31 | 14.97% | Rs3.91 Billion ≈ $42.28 Million |
Rs26.12 Billion ≈ $282.50 Million |
-0.43pp |
| 2004-03-31 | 15.40% | Rs3.42 Billion ≈ $36.98 Million |
Rs22.20 Billion ≈ $240.10 Million |
-- |
About Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, suc… Read more